← Back to patent-cliff list
Admilparant
Tier C — Watch / tradeAdmilparant
Bristol Myers Squibb
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：LPAR1
Indications (approved)：Pulmonary fibrosis, Idiopathic pulmonary fibrosis, Renal impairment, End-stage renal disease, Hepatic function decline
Regional status
US
Phase III
2023-09-14
EU
Phase III
2023-09-14
China
Phase III
2023-09-14
Japan
Phase III
2023-09-14
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Admilparant?
Approved indications include: Pulmonary fibrosis, Idiopathic pulmonary fibrosis, Renal impairment, End-stage renal disease, Hepatic function decline.
When does the Admilparant patent expire?
No public expiry year is available for Admilparant yet; this page updates once verified.
How do I get a quote for Admilparant intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02